NLS Pharmaceutics (NLSP) Competitors $2.32 +0.05 (+2.20%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.37 +0.05 (+2.16%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. ANVS, PLUR, MDCX, KPTI, EGRX, ACRV, PEPG, AKTX, XCUR, and BRNSShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Annovis Bio (ANVS), Pluri (PLUR), Medicus Pharma (MDCX), Karyopharm Therapeutics (KPTI), Eagle Pharmaceuticals (EGRX), Acrivon Therapeutics (ACRV), PepGen (PEPG), Akari Therapeutics (AKTX), Exicure (XCUR), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors Annovis Bio Pluri Medicus Pharma Karyopharm Therapeutics Eagle Pharmaceuticals Acrivon Therapeutics PepGen Akari Therapeutics Exicure Barinthus Biotherapeutics NLS Pharmaceutics (NASDAQ:NLSP) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Do analysts prefer NLSP or ANVS? Annovis Bio has a consensus price target of $18.00, indicating a potential upside of 611.46%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is NLSP or ANVS more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Annovis Bio N/A -300.56%-193.50% Do insiders & institutionals have more ownership in NLSP or ANVS? 15.8% of Annovis Bio shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, NLSP or ANVS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$1.98MN/AN/AAnnovis BioN/AN/A-$24.59M-$2.16-1.17 Does the media refer more to NLSP or ANVS? In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, NLSP or ANVS? NLS Pharmaceutics has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. SummaryAnnovis Bio beats NLS Pharmaceutics on 7 of the 10 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.17M$2.68B$5.50B$8.95BDividend YieldN/A1.79%5.25%4.04%P/E RatioN/A8.9826.9720.11Price / SalesN/A714.59425.92119.81Price / CashN/A159.8036.8257.86Price / Book-6.274.517.985.56Net Income-$1.98M$31.26M$3.16B$248.40M7 Day Performance-9.73%3.57%2.36%4.67%1 Month Performance-15.64%1.28%2.15%6.64%1 Year Performance1,221.94%1.08%33.78%21.31% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$2.32+2.2%N/A+1,192.5%$8.17MN/A0.006ANVSAnnovis Bio1.6439 of 5 stars$2.18+6.3%$30.25+1,287.6%-83.6%$39.95MN/A-1.013PLURPluri3.5411 of 5 stars$4.95-2.8%$12.00+142.4%-3.8%$39.87M$330K-0.90150News CoveragePositive NewsGap DownMDCXMedicus Pharma2.5368 of 5 stars$2.99+3.1%$23.50+686.0%N/A$39.36MN/A-2.58N/ANews CoverageUpcoming EarningsGap UpKPTIKaryopharm Therapeutics3.8168 of 5 stars$4.31-1.8%$43.20+902.3%-60.8%$37.93M$145.24M-0.32380EGRXEagle PharmaceuticalsN/A$2.90+7.4%N/A-45.9%$37.66M$257.55M0.00100ACRVAcrivon Therapeutics2.3371 of 5 stars$1.19-0.8%$17.71+1,388.6%-81.5%$37.63MN/A-0.5458PEPGPepGen2.9105 of 5 stars$1.11-3.5%$7.67+590.7%-93.1%$37.63MN/A-0.3530AKTXAkari Therapeutics1.5161 of 5 stars$1.17+0.9%N/A-61.1%$37.30MN/A0.009News CoverageXCURExicure1.3407 of 5 stars$7.04+19.5%N/A+2,197.5%$37.21M$500K-1.8450Gap UpHigh Trading VolumeBRNSBarinthus Biotherapeutics2.5496 of 5 stars$0.93+1.5%$6.25+572.0%-31.1%$36.95M$14.97M-0.57107News Coverage Related Companies and Tools Related Companies Annovis Bio Alternatives Pluri Alternatives Medicus Pharma Alternatives Karyopharm Therapeutics Alternatives Eagle Pharmaceuticals Alternatives Acrivon Therapeutics Alternatives PepGen Alternatives Akari Therapeutics Alternatives Exicure Alternatives Barinthus Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLSP Stock Alerts